By InvitationPhase 2

Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery

Kuwait30 participantsStarted 2019-10-22

Plain-language summary

This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.

Who can participate

Age range21 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. People diagnosed with type 2 diabetes prior to bariatric surgery.
✓. People did not have diabetes prior to bariatric surgery.
✓. Willing to participate in this study.

Exclusion criteria

✕. Type 1 diabetes
✕. Secondary diabetes
✕. History of ketoacidosis
✕. History of pancreatitis and pancreatectomy.
✕. History of primary renal glycosuria or hereditary glucose-galactose malabsorption.
✕. Active diabetes complications, nephropathy (dipstick positive proteinuria, or reduced eGFR (\<60 ml/min), proliferative retinopathy.
✕. Clinically significant abnormal liver function test.
✕. Pregnant ladies, or intending pregnancy or breastfeeding.

What they're measuring

Time spent below 3 mmol/L and above 10 mmol/L on and off dapagliflozin

Timeframe: 12 weeks

Trial details

NCT IDNCT07515391

SponsorDasman Diabetes Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-05-01

View on ClinicalTrials.gov More Bariatric Surgery Candidate trials